Skip to content

Autonomic Regulation Therapy in Heart Failure With Preserved Ejection Fraction

Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure With Preserved Ejection Fraction (ANTHEM-HFpEF) Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03163030
Enrollment
52
Registered
2017-05-22
Start date
2014-08-31
Completion date
2021-12-31
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Keywords

Heart Failure, Preserved Ejection Fraction, VNS, Vagus Nerve, Autonomic Regulation Therapy

Brief summary

The ANTHEM-HFpEF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart failure with preserved and mid-range ejection fraction.

Detailed description

Heart failure patients will be enrolled and implanted with a cervical VNS system on the right side. After a 2-week post-implantation recovery period and a 10-week stimulation titration period, continuous periodic stimulation will be performed for 12 months, with data collection at 3, 6, 9, and 12 months.

Interventions

Electrical Stimulation of the Vagus Nerve

Sponsors

Cyberonics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with symptomatic heart failure, New York Heart Association (NYHA) class II/III with preserved and mid-range EF (≥40%).

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Adverse Events12 monthsIncidence of procedure and device-related complications

Secondary

MeasureTime frameDescription
Functional Status (6MWD)12 months6-minute walk distance
Quality of Life Score12 monthsMinnesota Living with Heart Failure Questionnaire score
Functional Status (NYHA Class)12 monthsNew York Heart Association classification
Cardiac Size (LAVI)12 monthsLeft atrial volume index
Cardiac Size (LV mass index)12 monthsLeft ventricular mass index
Autonomic Function (HRV)12 monthsHeart rate variability
Blood Biomarkers12 monthsBlood Levels of Heart Failure Biomarkers (NT-proBNP, creatinine, C-reactive protein)
Cardiac Function (E/E')12 monthsRatio of mitral velocity to early diastolic velocity of the mitral annulus

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026